STAAR Surgical (NASDAQ:STAA) Shares Gap Down – Should You Sell?

STAAR Surgical (NASDAQ:STAA) shares gapped down before the market opened on Monday . The stock had previously closed at $29.10, but opened at $28.26. STAAR Surgical shares last traded at $28.00, with a volume of 44,692 shares trading hands.

Wall Street Analyst Weigh In

STAA has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Finally, Stifel Nicolaus cut their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical currently has an average rating of “Hold” and a consensus target price of $43.33.

STAAR Surgical Stock Down 4.5 %

The company has a 50 day moving average of $30.58 and a 200 day moving average of $36.06. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 66.14 and a beta of 0.61.

Institutional Trading of STAAR Surgical

Institutional investors and hedge funds have recently bought and sold shares of the company. Arcadia Investment Management Corp MI acquired a new stake in STAAR Surgical during the third quarter valued at approximately $37,000. Quarry LP acquired a new stake in STAAR Surgical during the third quarter valued at approximately $50,000. Canada Pension Plan Investment Board acquired a new stake in shares of STAAR Surgical during the 2nd quarter worth approximately $129,000. Larson Financial Group LLC acquired a new stake in shares of STAAR Surgical during the 2nd quarter worth approximately $130,000. Finally, Quest Partners LLC acquired a new stake in shares of STAAR Surgical during the 3rd quarter worth approximately $128,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.